Psychiatric comorbidity is associated with disability progression in multiple sclerosis.

Neurology

From the Department of Medicine (K.A.M., H.T., L.K.), Division of Neurology and Centre for Brain Health, University of British Columbia, Vancouver; Department of Medicine (J.D.F., T.C.) and School of Nursing, Faculty of Health Professions (T.C.), Dalhousie University, Halifax, Canada; Department of Health Services, Policy & Practice (T.Z.), Brown University School of Public Health, Providence, RI; Departments of Psychiatry and Community Health Sciences (S.B.P.), Cumming School of Medicine, University of Calgary; and Departments of Internal Medicine and Community Health Sciences (R.A.M.), Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada.

Published: April 2018

Objective: Emerging evidence suggests that comorbidity may influence disability outcomes in multiple sclerosis (MS); we investigated the association between psychiatric comorbidity and MS disability progression in a large multiclinic population.

Methods: This retrospective cohort study accessed prospectively collected information from linked clinical and population-based health administrative databases in the Canadian provinces of British Columbia and Nova Scotia. Persons with MS who had depression, anxiety, or bipolar disorder were identified using validated algorithms using physician and hospital visits. Multivariable linear regression models fitted using an identity link with generalized estimating equations were used to determine the association between psychiatric comorbidity and disability using all available Expanded Disability Status Scale (EDSS) scores.

Results: A total of 2,312 incident cases of adult-onset MS were followed for a mean of 10.5 years, during which time 35.8% met criteria for a mood or anxiety disorder. The presence of a mood or anxiety disorder was associated with a higher EDSS score (β coefficient = 0.28, = 0.0002, adjusted for disease duration and course, age, sex, socioeconomic status, physical comorbidity count, and disease-modifying therapy exposure). Findings were statistically significant among women (β coefficient = 0.31, = 0.0004), but not men (β coefficient 0.22, = 0.17).

Conclusion: Presence of psychiatric comorbidities, which were common in our incident MS cohort, increased the severity of subsequent neurologic disability. Optimizing management of psychiatric comorbidities should be explored as a means of potentially mitigating disability progression in MS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5894930PMC
http://dx.doi.org/10.1212/WNL.0000000000005302DOI Listing

Publication Analysis

Top Keywords

psychiatric comorbidity
12
disability progression
12
multiple sclerosis
8
association psychiatric
8
comorbidity disability
8
mood anxiety
8
anxiety disorder
8
psychiatric comorbidities
8
disability
7
psychiatric
5

Similar Publications

Importance: Depression and antidepressant use are independently associated with crash risk among older drivers. However, it is unclear what factors impact daily driving that increase safety risk for drivers with depression.

Objective: To examine differences in naturalistic driving behavior and safety between older adults with and without major depressive disorder (MDD).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South).

Background: Plasma biomarkers for Alzheimer's disease (AD) have demonstrated their accuracy as diagnostic tools, suggesting their impending integration into clinical practice. Medical comorbidities might not only affect AD pathological burdens but also cause variability of plasma biomarkers by affecting their transfer via blood brain barriers. In the present study, we aimed to determine which comorbidities might affect plasma biomarkers with (real effects) or without (biological variability) AD pathological burdens measured by β-amyloid (Aβ) uptakes on PET.

View Article and Find Full Text PDF

Background: The initiation of cognitive impairment is triggered by a myriad of pathological events occurring decades before clinical symptoms manifest. Perturbed glucose and fatty acid metabolism notably contribute to the development of cognitive impairment, progressing further into clinical dementia. These metabolic alterations are evident in plasma through changes in specific metabolites.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Salud Carlos III, Madrid, Spain.

Background: Co-morbid Alzheimer's disease (AD) pathology is a major risk factor for cognitive impairment (CI) in PD, but whether and how AD co-pathology affects the clinical phenotype of PD-CI is incompletely understood. Recently validated plasma biomarkers for AD pathology, such as ptau217, hold great promise to revolutionize the diagnosis of neurodegenerative diseases. Here, we used plasma ptau217 to detect AD co-pathology in a well-characterized cohort of PD patients with CI and examine its associations with APOE4 genotype, cognitive profile, and cerebral hypometabolism on FDG-PET.

View Article and Find Full Text PDF

Public Health.

Alzheimers Dement

December 2024

University of California, San Francisco, San Francisco, CA, USA.

Background: Growing evidence reports an association between sleep-disordered breathing (SDB) and cognitive impairment, including mild cognitive impairment (MCI) and dementia. However, there is limited research on the link between cognitive impairment and in-home measures of SDB and how this association may differ by race, ethnicity, and sex.

Method: We studied 822 individuals who were enrolled in the community-based Health and Aging Brain Study-Health Disparities (HABS-HD)-Dormir study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!